At the news
? NEUTRALIMPACT 3/10 CLUSTER filed Jun 10, 2026 at 16:30 ET
Nuvalent CEO James Porter exercised 30,000 options at $18.93/share and sold 12,495 shares on the open market for $1.1M, while CFO Alexandra Balcom sold 960 shares for $91K. These sales occurred just one day after the announcement of GSK's $10.6B acquisition of Nuvalent at $124/share, suggesting the CEO's sale was likely pre-planned (option exercise + sell-to-cover) rather than a bearish signal. The cluster is trivial relative to the $9.7B market cap (0.01%) and is overshadowed by the transformative acquisition premium.
- CEO Porter exercised 30,000 options at $18.93/share ($567,900) and sold 12,495 shares at $87.97 ($1.1M) on June 8, 2026
- CFO Balcom sold 960 shares at $94.87 ($91K) on June 1, 2026
- Total insider sales of $1.19M represent ~0.01% of Nuvalent's $9.7B market cap
- GSK acquisition at $124/share (43% premium to recent price) was announced June 9, 2026, one day after the CEO's sale
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access